Somatuline Depot and Alcohol/Food Interactions
There is 1 alcohol/food/lifestyle interaction with Somatuline Depot (lanreotide).
Lanreotide Food
Moderate Food Interaction
MONITOR: Due to their gastrointestinal pharmacologic effects, somatostatin analogs (e.g., octreotide, lanreotide) may variously affect the absorption of dietary nutrients and concomitantly administered oral medications. Somatostatin analogs have been shown to prolong gastrointestinal transit time and inhibit intestinal absorption of some nutrients such as fat. Clinical data are limited, however. In case reports, octreotide has been reported to reduce the relative bioavailability of cyclosporine. Transplant rejection and significant reductions in cyclosporine levels, sometimes to undetectable levels, have been reported in association with the interaction. Vitamin K absorption was not affected when concomitantly administered with lanreotide according to the manufacturer.
MANAGEMENT: Clinicians should be aware of the potential for altered absorption of concomitantly administered oral medications during treatment with somatostatin analogs. Blood levels and clinical response should be monitored, particularly for drugs that have a narrow therapeutic index, and the dosages adjusted as necessary.
References (5)
- Landgraf R, Landgraf-Leurs MM, Nusser J, et al. (1987) "Effect of somatostatin analogue (SMS201-995) on cyclosporine levels." Transplantation, 44, p. 724-5
- Ho PJ, Boyajy LD, Greenstein E, Barkan AL (1993) "Effect of chronic octreotide treatment on intestinal absorption in patients with acromegaly." Dig Dis Sci, 38, p. 309-15
- Katz MD, Erstad BL (1989) "Octreotide, a new somatostatin analogue." Clin Pharm, 8, p. 255-73
- (2001) "Product Information. Sandostatin (octreotide)." Sandoz Pharmaceuticals Corporation
- (2007) "Product Information. Somatuline Depot (lanreotide)." Ipsen Inc
Switch to consumer interaction data
Somatuline Depot drug interactions
There are 164 drug interactions with Somatuline Depot (lanreotide).
Somatuline Depot disease interactions
There are 7 disease interactions with Somatuline Depot (lanreotide) which include:
- hepatic impairment
- renal impairment
- thyroid abnormalities
- adrenal insufficiency
- bradycardia
- cholelithiasis
- diabetes
More about Somatuline Depot (lanreotide)
- Somatuline Depot consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (1)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- Generic availability
- FDA approval history
- Drug class: somatostatin and somatostatin analogs
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Cabometyx
Cabometyx is used to treat advanced kidney cancer, liver cancer, thyroid cancer, and pancreatic and ...
Afinitor
Afinitor prevents the growth of cancer cells and is used to treat advanced kidney cancer. Learn ...
Lutathera
Lutathera is a targeted radiotherapy used for gastroenteropancreatic neuroendocrine tumors ...
Cometriq
Cometriq (cabozantinib) is used to treat thyroid cancer that has spread to other parts of the body ...
Zortress
Zortress (everolimus) is used to prevent organ rejection in adult kidney transplant recipients ...
Lutetium lu 177 dotatate
Lutetium Lu 177 Dotatate (Lutathera) is a targeted radiotherapy used for gastroenteropancreatic ...
Cabozantinib
Cabozantinib is used for hepatocellular carcinoma, neuroendocrine tumors, renal cell carcinoma ...
Everolimus
Everolimus (Afinitor, Afinitor Disperz, Zortress) belongs to a class of drugs called kinase ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.